Ocifisertib (fumarate)

CFI-400945 fumarate is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.

Product Specifications

CAS Number

[1616420-30-4]

Product Name Alternative

CFI-400945 (fumarate)

UNSPSC

12352005

Target

Polo-like Kinase (PLK)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cc_fumarate_.html

Concentration

10mM

Purity

99.27

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC(/C=C/C(O)=O)=O.O=C1[C@@]2(C3=CC(OC)=CC=C3N1)[C@H](C4=CC=C(C(/C=C/C5=CC=C(C=C5)CN6C[C@H](O[C@H](C6)C)C)=NN7)C7=C4)C2

Molecular Formula

C37H38N4O7

Molecular Weight

650.72

References & Citations

[1]Sampson PB, et al. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S) .2- (3- ((E) .4- (((cis) .2,6-dimethylmorpholino) methyl) styryl) . 1H.indazol-6-yl) -5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent. J Med Chem. 2015 Jan 8;58 (1) :147-69.|[2]Mason JM, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26 (2) :163-76.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

PLK4

Citation 01

Int J Mol Med. 2021 Jan;47 (1) :151-160.|Ir J Med Sci. 2023 Apr;192 (2) :561-567.|J Cancer Res Clin Oncol. 2020 Nov;146 (11) :2871-2883.|Nat Nanotechnol. 2021 Jul;16 (7) :830-839.